Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

9,844 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges.
Earnshaw SR, Wilson M, Mauskopf J, Joshi AV. Earnshaw SR, et al. Among authors: wilson m. Value Health. 2009 Jun;12(4):507-20. doi: 10.1111/j.1524-4733.2008.00467.x. Epub 2008 Nov 10. Value Health. 2009. PMID: 19900253 Review.
Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage.
Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Earnshaw SR, et al. Among authors: wilson mr. Stroke. 2006 Nov;37(11):2751-8. doi: 10.1161/01.STR.0000246611.21999.5d. Epub 2006 Sep 28. Stroke. 2006. PMID: 17008607
The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets.
Earnshaw SR, Wilson MR, Joshi AV. Earnshaw SR, et al. Among authors: wilson mr. Manag Care Interface. 2006 Nov;19(11):39-45. Manag Care Interface. 2006. PMID: 17137241
Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
Earnshaw SR, Wilson MR, Dalal AA, Chambers MG, Jhingran P, Stanford R, Mapel DW. Earnshaw SR, et al. Among authors: wilson mr. Respir Med. 2009 Jan;103(1):12-21. doi: 10.1016/j.rmed.2008.10.005. Epub 2008 Nov 17. Respir Med. 2009. PMID: 19010652
Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.
Hauber AB, Fleischmann J, Lothgren M, Wilson M, Lam A, Dubois D, Sabatowski R. Hauber AB, et al. Among authors: wilson m. J Opioid Manag. 2011 Jul-Aug;7(4):287-96. doi: 10.5055/jom.2011.0070. J Opioid Manag. 2011. PMID: 21957828
Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia.
Wilson M, Gutierrez B, Offord SJ, Blanchette CM, Eramo A, Earnshaw S, Kamat SA. Wilson M, et al. Drugs Context. 2016 Mar 11;5:212273. doi: 10.7573/dic.212273. eCollection 2016. Drugs Context. 2016. PMID: 27114739 Free PMC article.
Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Wilson MR, et al. Eur J Health Econ. 2018 Mar;19(2):229-240. doi: 10.1007/s10198-017-0879-5. Epub 2017 Mar 8. Eur J Health Econ. 2018. PMID: 28271250
Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR. Wilson MR, et al. Int J Chron Obstruct Pulmon Dis. 2017 Mar 24;12:997-1008. doi: 10.2147/COPD.S124420. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28392684 Free PMC article.
Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK.
Wilson MR, Azzabi Zouraq I, Chevrou-Severac H, Selby R, Kerrigan MC. Wilson MR, et al. Clinicoecon Outcomes Res. 2017 Oct 16;9:641-652. doi: 10.2147/CEOR.S135609. eCollection 2017. Clinicoecon Outcomes Res. 2017. PMID: 29081667 Free PMC article.
Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada.
Wilson M, Wasserman M, Jadavi T, Postma M, Breton MC, Peloquin F, Earnshaw S, McDade C, Sings H, Farkouh R. Wilson M, et al. Infect Dis Ther. 2018 Sep;7(3):353-371. doi: 10.1007/s40121-018-0206-1. Epub 2018 Jun 22. Infect Dis Ther. 2018. PMID: 29934878 Free PMC article.
9,844 results
Jump to page
Feedback